Sign in Subscribe
Communicable diseases

Oncolytic Virus Demonstrates Selectivity, Efficacy, and Lack of Toxicity

Strategic Insights

— 1 min read

Scientists at Genetic Therapy, Inc., a subsidiary of Novartis, and Cell Genesys, Inc. have published a study in the August 2004 issue of Cancer Gene Therapy demonstrating a novel oncolytic virus, CG 4030, which exhibits selectivity, efficacy, and lack of toxicity. This virus is engineered with two tumor-selective promoters, the telomerase promoter and the E2F-1 promoter, driving essential genes for viral replication. The results show that the virus effectively kills multiple human cancer cell lines while sparing normal cells, including primary liver cells.

Key Takeaways:

  • The oncolytic adenovirus, CG 4030, contains two tumor-selective promoters, the telomerase promoter and the E2F-1 promoter, which drive genes essential for viral replication.
  • In vitro assays demonstrated the virus's ability to kill multiple human cancer cell lines while having minimal effect on normal cells, including cultures of primary liver cells.
  • The virus was found to be well-tolerated and less toxic than an earlier version in normal liver cells.
  • In mice bearing human liver and prostate tumors, the virus resulted in significant reduction in tumor growth, including complete tumor regression in 80% of animals bearing human prostate cancer tumors.
  • The combination of the virus and doxorubicin, a commonly used chemotherapeutic agent, showed improved antitumor activity compared to either agent alone.
  • The study's findings suggest that the dual-promoter oncolytic adenovirus, CG 4030, is a promising approach to treating cancer.

Statistics:

  • 90% of all human cancers are driven by the telomerase promoter.
  • 85% of all human cancers have a defective Rb pathway, which is active in the E2F-1 promoter.
  • In vitro cell culture studies showed the virus killed multiple human cancer cell lines with minimal toxicity to normal cells.
  • The virus was administered intravenously to mice bearing human liver and prostate tumors, resulting in significant reduction in tumor growth.
  • 80% of mice bearing human prostate cancer tumors experienced complete tumor regression following a single intravenous injection of the virus.
  • The combined administration of the virus and doxorubicin resulted in a 50% increase in antitumor activity compared to either agent alone.

Sources:

  • (NewsRx.com & NewsRx.net, 2004 SEP 13)
  • Genetic Therapy, Inc.
  • Novartis, AG
  • Cell Genesys, Inc.
  • Cancer Gene Therapy (Journal) August 2004 issue

Read more